A polysaccharide-based bioadhesive hydrogel
Highlights Proprietary adhesive patches for novel drug delivery with improved patch-skin adhesion and biocompatibility. Work in a range of pHs, provide better adhesion and higher permeation than commercial patches. Proof of concept was shown in several in-vivo and in-vitro models. These novel patches will serve as a platform for transdermal and topical drug delivery. Our Innovation The patches are adhesives based on chemically and physically modified polysaccharides, which are partially depolymerised providing a more effective topical and transdermal drug delivery system. All tested patches were found to be highly adhesive while providing superior drug penetration. Key Features Novel and natural drug carrier applicable for a broad range of drugs More effective topical and transdermal drug delivery system Improved adhesiveness and elasticity Superior drug delivery High manufacturability, entailing flexible pricing strategy All exudates used are generally recognized as safe (GRAS) and are FDA approved Development Milestones In vivo studies testing various compositions of the patches enhancing adhesiveness and drug permeability The Opportunity Annual U.S. market for transdermal patches alone is more than $3 billion. Replace current commercial patches applying many of the currently used drugs such as clonidine, fentanyl, lidocaine, nicotine, nitroglycerin, oestradiol, oxybutinin, scopolamine, and testosterone. The number of drug therapies being developed in patch form is expanding.
Type of Offer: Licensing
« More Material Science Patents